Table 7.
Interaction | Treatments | Claudin-3 | MUC-2 | TFF-2 | ZO-1 |
---|---|---|---|---|---|
Day 17 | Control | 1.00a,b | 1.02a,b | 0.99a,b | 1.00a,b |
CP | 0.95a,b | 0.51e | 0.51c | 0.59c | |
CA | 1.00a,b | 1.05a,b | 0.95a,b | 1.05a | |
CA + CP | 0.99a,b | 0.92b,c | 0.89b | 1.04a | |
AB | 0.99a,b | 0.98b | 0.99a,b | 0.99a,b | |
AB + CP | 0.93b | 0.83c | 0.81b | 0.97a,b | |
Day 21 | Control | 0.99a,b | 0.99b | 1.00a | 1.03a |
CP | 0.63c | 0.70d | 0.49c | 0.14d | |
CA | 1.03a | 1.11a | 0.95a,b | 0.99a,b | |
CA + CP | 0.93b | 0.98b | 0.88b | 1.06a | |
AB | 1.02a | 0.98b | 1.01a | 0.99a,b | |
AB + CP | 1.00a,b | 0.86c | 0.87b | 0.91b | |
SEM | 0.03 | 0.037 | 0.037 | 0.04 | |
Stage | |||||
Day 17 | 0.98a | 0.88b | 0.86 | 0.94a | |
Day 21 | 0.93b | 0.94a | 0.87 | 0.85b | |
SEM | 0.012 | 0.015 | 0.015 | 0.016 | |
Treatments | |||||
Control | 1.00a | 1.00a,b | 1.00a | 1.02a,b | |
CP | 0.79b | 0.60d | 0.50c | 0.36c | |
CA | 1.02a | 1.08a | 0.95a,b | 1.02a,b | |
CA + CP | 0.96a | 0.95b | 0.88b | 1.05a | |
AB | 1.00a | 0.98b | 1.00a | 0.99a,b | |
AB + CP | 0.96a | 0.84c | 0.84b | 0.94b | |
SEM | 0.021 | 0.026 | 0.026 | 0.028 | |
P-values | |||||
Stage | 0.017 | 0.021 | 0.639 | 0.001 | |
Treatments | <0.001 | <0.001 | <0.001 | <0.001 | |
Stage × Treatments | <0.001 | 0.088 | 0.910 | <0.001 |
In the same line, the same letter superscripts mean no significant difference (P > 0.05), and the different letter superscripts mean significant difference (P < 0.05).
Abbreviations: AB, antibiotic group; AB + CP, antibiotic + C. perfringens group; CA, chlorogenic acid group; CA + CP, chlorogenic acid + C. perfringens group; CP, Clostridium perfringens group; SPF, specific-pathogen-free.